Skip to main content
. 2021 Dec 15;2(3):185–193. doi: 10.2478/rir-2021-0024

Figure 5.

Figure 5

Reduced lupus disease manifestations in BDF1 mice treated with TFH-targeted NPs. Proteinuria (A) and survival (B) were monitored in treated mice and controls at the times indicated on the x-axes. n = 5 per group; *P < 0.05 vs. untargeted NPs. NPs, nanoparticles; TFH, T follicular helper cells.